Join
today

Boliven PRO is more than just patent search

  • Build and save lists using the powerful Lists feature
  • Analyze and download your search results
  • Share patent search results with your clients

Patents »

US7326535: Immunoreactive peptides from Epstein-Barr virus

Share

Filing Information

Inventor(s) Richard S. Smith · Gary R. Pearson · D. Elliot Parks · Susan Pothen Varghese ·
Assignee(s) Ortho Diagnostic Systems Inc. · Georgetown University ·
Attorney/Agent(s) Woodcock Washburn LLP ·
Primary Examiner Ronald B. Schwadron ·
Application Number US10442456
Filing date 05/21/2003
Issue date 02/05/2008
Prior Publication Data
Predicted expiration date 06/30/2015
Patent term adjustment 653
U.S. Classifications 435/71  · 530/325  · 435/792  · 436/518  · 436/820  · 530/324  · 435/5  · 530/326  · 424/186.1  · 424/193.1  · 424/230.1  · 435/79  ·
International Classifications G01N3353  · G01N33543  · G01N33569  · G01N3358  ·
Kind CodeB2
Related U.S. Application DataCROSS-REFERENCE TO RELATED APPLICATIONS
This patent application is a divisional of application Ser. No. 08/392,934, filed on Oct. 28, 1996, now U.S. Pat. No. 7,060,283, issued Jun. 13, 2006, which is a National Phase of International patent application Ser. No. PCT/US93/08699, filed on Sep. 15, 1993, which claims priority of patent application Ser. No. 07/945,280, filed on Sep. 15, 1992 (abandoned). The disclosures of each of the foregoing applications is hereby incorporated by reference in its entirety.
5 Claims, 7 Drawings


Abstract

Epstein-Barr virus (EBV) specific polypeptides are disclosed. Also disclosed are the use of these polypeptides for the production of polypeptide-specific antibodies and the diagnosis and treatment of EBV-associated disease.

Independent Claims | See all claims (5)

  1. 1. A method for detecting antibody to a polypeptide consisting of an amino acid sequence of formula: (φ)n wherein n is 1 to about 1000 and φ is 25 amino acids or less and has the formula: (α ETFTETWNRFITHTE β)n (SEQ. ID NO:1) (α GMLEASEGLDGWIHQ β)n (SEQ. ID NO:2) (α HQQGGWSTLIEDNIP β)n (SEQ. ID NO:3) or (α KQKHPKKVKQAFNPL β)n (SEQ. ID NO:4) wherein α and β are independently from 0 to about 5 naturally occurring amino acids, wherein the polypeptide is capable of binding antibody in a specimen from an individual with Epstein-Barr virus (EBV)-associated disease, which comprises contacting a specimen with the polypeptide and determining whether antibody binds to the peptide.

References Cited

U.S. Patent Documents

Document NumberAssigneesInventorsIssue/Pub Date
US3654090 Schuurs et al. Apr 1972
US3654090 Schuurs et al. Apr 1972
US3850752 AKZONA INC Schuurs et al. Nov 1974
US4016043 Akzona Incorporated Schuurs et al. Apr 1977
US4172124 The Wistar Institute Koprowski et al. Oct 1979
US4196265 The Wistar Institute Koprowski et al. Apr 1980
US4629783 Genetic Systems Corporation Cosand Dec 1986
US4879213 Scripps Clinic and Research Foundation Fox et al. Nov 1989

Foreign Patent Documents

Document NumberAssigneesInventorsIssue/Pub Date
EP0173254Hans Joachim WolfMar 1986
EP0280813SCRIPPS CLINIC AND RESEARCH FOUNDATIONSep 1988
WO199108224Jun 1991
WO199406470Mar 1994
WO199408597Apr 1994

Other Publications

Baer et al., DNA Sequence and Expression of the B95-8 Epstein Barr Virus Genome, Nature 310: 207-211 (Jul. 1984).
Burton et al., “A Large Array of Human Monoclonal Antibodies to Type 1 Human Immunodeficiency Virus from Combinatorial Libraries of Asymptomatic Seropositive Individuals” Proc. Natl. Acad. Sci. USA vol. 88: 10134-10137 (Nov. 1991).
Curtiss, L.K. et al., “Localization of Two Epitopes of Apolipoprotein A-I That are Exposed on Human High Density Lipoproteins Using Monoclonal Antibodies and Synthetic Peptides”, J. Biol. Chem., vol. 263, No. 27: 13779-13785 (Sep. 1988).
Diener et al., “Specific Immunosuppression by Immunotoxins Containing Daunomycin” Science vol. 231: 148-150 (Jan. 1986).
Dillner et al., “Antibodies Against a Synthetic Peptide Identify the Epstein-Barr Virus-Determined Nuclear Antigen” Proc. Natl. Acad. Sci USA 81: 4652-4656 (Aug. 1984).
Douillard, J.Y. and Hoffman, “Monoclonal Antibodies Specific Immunotherapy of Gastrointestinal Tumors” T., Hyrbidoma 5 Supp 1: S139-S149 (Jul. 1986).
Eisenlohr et al., “Flanking Sequences Influence the Presentation of an Endogenously Synthesized Peptide to Cytotoxic T Lymphocytes” J. Exp Med. vol. 175: 481-487 (Feb. 1992).
Fox et al., “Synthetic Peptide Derived From the Epstein-Barr Virus Encoded Early Diffuse Antigen (EA-D)-Reactive with Human Antibodies” J. Clin. Lab. Anal. 1:140-145 (1987).
Greiner et al., “Recombinant Interferon Enhances Monoclonal Antibody-Targeting of Carcinoma Lesions in Vivo” Science vol. 235, No. 4791: 895-898 (Feb. 1987).
Gull Laboratories, EBV-EA Test, Product No. EA100 (1988, Revised Jul. 1989).
Henle et al, “Epstein-Barr Virus Specific Diagnostic Tests in Infectious Mononucleosis” Human Pathology vol. 5, No. 5: 551-565 (Sep. 1974).
Henle et al., “Demonstration of Two Distinct Components in the Early Antigen Complex of Epstein-Barr Virus-Infected Cells” Int. J. Cancer vol. 8, No. 3: 272-282 (Nov. 1971).
Herlyn et al., “Anti-Idiotypic Antibodies Bear the Internal Image of a Human Tumor Antigen” Science vol. 232, No. 4746: 100-102 (Apr. 1986).
Hinuma, Y. et al., “Immunofluorescence and Herpes-Type Virus Particles in the P3HR-1 Burkitt Lymphoma Cell Line” J. Virol. vol. 1, No. 5: 1045-1051 (Oct. 1967).
Jackman et al., “Expression of Epstein-Barr Virus gp350 as a Single Chain Glycoprotein for an EBV Subunit Vaccine” Vaccine 17: 660-668 (1999).
Jemmerson, “Effects of Conformation, Amino Acid Sequence, and Carrier Coupling on the Immunological Recognition of Peptide and Protein Antigens” Effects on Immunological Recognition of Peptides in Medicine And Biology, Edited by Zegers, Boersma, Classen, CRC Press Inc., New York Chapter 16, 213-225 (1995).
Köhler and Milstein, “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity” Nature: vol. 256, No. 5517 495-497 (Aug. 1975).
Lenard, J. et al., “Use of Hydrogen Fluoride in Merrifield Solid-Phase Peptide Synthesis” J. Am. Chem. Soc. vol. 89, No. 1: 181-182 (Jan. 1967).
Lerner, “Tapping the Immunological Repertoire to Produce Antibodies of Predetermined Specificity” Nature 299: 592-596 (Oct. 1982).
Luka et al., “A Sensitive Enzyme-Linked Immunosorbent Assay (ELISA) Against the Major EBV-Associated Antigens. I. Correlation between ELISA and Immunofluorescence Titers Using Purified Antigens” J. Immunol. Methods 67: 145-156 (1984).
Merrifield, “Solid Peptide Synthesis. I. The Synthesis of a Tetrapeptide”, J. Am. Chem. Soc. 85: 2149-2154 (Jul. 1963).
Oi et al., “Chimeric Antibodies”, Bio Techniques vol. 4, No. 3: 214-221 (May/Jun. 1986).
Ortho Diagnostic Systems, Inc. ORTHO *Eptstein-Barr Virus EA(D+R)-IgG Antibody ELISA Test for Detection of IgG Antibodies to the Early Antigen (EA) Diffuse and Restricted (D&R) Components of the Epstein-Barr Virus (EBV), Product Code 520025, 1-38 (Draft revised Aug. 20, 1993).
Pearson et al., “Application of Epstein-Barr Virus (EBV) Serology to the Diagnosis of North American Nasopharyngeal Carcinoma” Cancer 51: 260-268 (Jan. 1983).
Pearson et al. “Identification of an Epstein-Barr Virus Early Gene Encoding a Second Component of the Restricted Early Antigen Complex” Virology 160: 151-161 (1987).
Pothen et al., “Identification of T- and B-Cell Epitopes Associated with a Restricted Component of the Epstein-Barr Virus-Induced Early Antigen Complex” Int. J. Cancer 53: 199-204 (1993).
Pothen et al., “Human T-Cell Recognition of Epstein Barr Virus- Induced Replication Antigen Complexes” Int. J. Cancer 49: 656-660 (1991).
Rhodes et al., “Human Immune Reponses to Synthetic Peptides from the Epstein-Barr Nuclear Antigen” J. Immunol vol. 134, No. 1: 211-216 (Jan. 1985).
Smith et al. , “Antibodies to an Epstein-Barr Virus Nuclear Antigen Synthetic Peptide in Infectious Mononucleosis” Am. J. Clin. Pathology vol. 92 No. 4: 447-451 (Oct. 1989).
Spira et al., “The Identification of Monoclonal Class Switch Variants by Sib Selection and an ELISA Assay” J. Immunol. Methods 74: 307-315 (1984).
Steplewski et al., “Isolation and Characterization of Anti-Monosialoganglioside Monoclonal Antibody 19-9 Class-Switch Variants” Proc. Natl. Acad. Sci., USA, vol. 82: 8653-8657 (Dec. 1985).
Stewart and Young, “Laboratory Techniques in Solid Phase Peptide Synthesis” Solid Phase Peptides Synthesis (W. H. Freeman & Company, San Francisco, Chapter 2 pp. 27-64 (1969).
Sun et al., “Chimeric Antibodies with 17-1A-Derived Variable and Human Constant Regions” Hybridoma, vol. 5 Supplement 1: S17-S20 (1986).
Sutcliffe et al., “Antibodies That React With Predetermined Sites on Proteins” Science vol. 219, No. 4585: 660-666 (Feb. 1983).
Tainer et al, “The Reactivity of Anti-Peptide Antibodies is a Function of the Atomic Mobility of Sites in a Protein” Nature 312: 127-134 (Nov. 1984).
Ulaeto et al, “In Vitro T Cell Responses to a Candidate Epstein-Barr Virus Vaccine: Human CD 4+T-Cell Clones Specific for the Major Envelope Glycoprotein gp340” Eur. J. Immunol. 18: 1689-1697 (1988).
Waldmann, “Monoclonal Antibodies in Diagnosis and Therapy” Science 252: 1657-1662 (Jun. 1991).
Wolff et al, “The Use of Monoclonal ANTI-Thy1 IgG1 for the Targeting of Liposomes to AKR-A Cells in Vitro and in Vivo” Biochemica et Biophysica Acta, 802: 259-273 (1984).
Young “Epstein-Barr Virus” Encyclopedia of Virology, vol. 1, Edited by Webster and Granoff, Academic Press, 404-416 (1994).
Foong, Y.T. et al., “Serum and Salivary IgA Antibodies Against a Defined Epitope of the Epstein-Barr Virus Nuclear Antigen (EBNA are Elevated in Nasopharyngeal Carcinoma,” Int. J. Cancer, 1990, 45, 1061-1064.
Halprin, J. et al., “Enzyme-Linked Immunosorbent Assay of Antibodies to Epstein-Barr Virus Nuclear and Early Antigens in Patients with Infectious Mononucleosis and Nasopharyngeal Carinoma,” Annals of Internal Medicine, 1986, 104, 331-337.
Linde, A. et al., “Evaluation of Enzyme-Linked Immunosorbent Assays with Two Synthetic Peptides of Epstein-Barr Virus for Diagnosis of Infectious Mononucleosis,” Journal of Infectious Diseases, 1990, 161, 903-909.
Motz, M. et al., “Expression of the Epstein-Barr Virus 138-kDa Early Protein in Escherchia coli for the use as antigen diagnostic tests,” Gene, 1986, 42, 303-312.
Okano, M. et al., “Epstein-Barr Virus and Human Diseases: Recent Advances in Diagnosis,” Clinical Microbiology Reviews, 1988, 1(3), 300-312.
Pearson, G., “Identification of Polypeptide Components of the Epstein-Barr Virus early Antigen Complex with Monoclonal Antibodies,” Journal of Virology, 1983, 47(1), 193-201.
Smith, R.S. et al., “A Synthetic Peptide for Detecting Antibodies to Epstein-Barr Virus Nuclear Antigen in Sera from Patients with Infectious Mononucleosis,” Journal of Infectious Diseases, 1986, 154(5), 885-889.

Referenced By

The current document is not referenced by other documents.

Patent Family

Document NumberAssigneeInventorsIssue/Pub Date
US20040013665 Ortho Diagnostic Systems, Inc. Gary Pearson et al. Jan 2004
US7326535 Ortho Diagnostic Systems Inc. Richard S. Smith et al. Feb 2008